Blue Trust Inc’s Atea Pharmaceuticals AVIR Stock Holding History

Blue Trust Inc’s Portfolio AVIR Stock Details AVIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$46.8K	Hold	8,700	–	–	﹤0.01%	1357
2025 Q4	$31.1K	Hold	8,700	–	–	﹤0.01%	1527
2025 Q3	$25.2K	Hold	8,700	–	–	﹤0.01%	1605
2025 Q2	$31.3K	Hold	8,700	–	–	﹤0.01%	1568
2025 Q1	$26K	Hold	8,700	–	–	﹤0.01%	1581
2024 Q4	$29.1K	Hold	8,700	–	–	﹤0.01%	1504
2024 Q3	$28.8K	Hold	8,700	–	–	﹤0.01%	1801
2024 Q2	$35.1K	Hold	8,700	–	–	﹤0.01%	1413
2024 Q1	$35.1K	Hold	8,700	–	–	﹤0.01%	1038
2023 Q4	$26K	Hold	8,700	–	–	﹤0.01%	1183
2023 Q3	$33K	Hold	8,700	–	–	﹤0.01%	994
2023 Q2	$29K	Hold	8,700	–	–	﹤0.01%	899
2023 Q1	$42K	Hold	8,700	–	–	﹤0.01%	1100
2022 Q4	$50K	Hold	8,700	–	–	﹤0.01%	914
2022 Q3	$62K	Hold	8,700	–	–	﹤0.01%	678
2022 Q2	$63K	Buy	+8,700	New	+$59.4K	﹤0.01%	627

Other funds holding AVIR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Blue Trust Inc's AVIR Position: Q1 2026 in Review

Blue Trust Inc held its Atea Pharmaceuticals (AVIR) position steady in Q1 2026 at 8,700 shares worth $46.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1357.

Blue Trust Inc first reported a position in AVIR in Q2 2022 and has held it in 16 quarters since. The position peaked at $63K in Q2 2022. 127 funds tracked by Wall St. Rank hold AVIR as of Q1 2026.

Blue Trust Inc held 8,700 shares of Atea Pharmaceuticals worth $46.8K as of Q1 2026.
Blue Trust Inc left its Atea Pharmaceuticals share count unchanged in Q1 2026.
Atea Pharmaceuticals made up ﹤0.01% of Blue Trust Inc's portfolio in Q1 2026, its #1357 holding.
Blue Trust Inc first reported a position in Atea Pharmaceuticals in Q2 2022 and has held it in 16 quarters since.
Blue Trust Inc's Atea Pharmaceuticals position peaked at $63K in Q2 2022.
127 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2026.

Based on Blue Trust Inc's 13F filing for Q1 2026, filed 20 Apr 2026.